• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Legal - Articles and news items

visa

Immigration strategies for effectively relocating to the US

Blog / 6 November 2015 / Ashley Puscas, Associate Attorney at Laura Devine Attorneys

In our globalised economy, it is more common than ever to see pharma companies expanding to establish a presence in multiple markets. Here Ashley Puscas discusses the immigration pathways for pharma seeking to relocate or expand in the US…

RightsDirect Whitepaper

Whitepaper: Managing Copyright Compliance in Life Sciences

Whitepapers / 11 March 2014 / RightsDirect

Can purchased or free scientific content be reused or shared? Not necessarily, as the free white paper from RightsDirect explains…

is it ever right to sue a client?

Issue 2 2011, Patents / 19 April 2011 / Jim Kinnier Wilson, Partner, Manches

Imagine that you are part of a small biotech company, BiotechCo, whose business is the development of delivery systems for pharmaceutical products. One of your team, who is in charge of developing sales with a large pharmaceutical company, Pharma Co, came to you three months ago with the possibility of a very interesting contract within that company. You went to a meeting where various things were discussed on a confidential basis. As a result of that, you now have a clearer idea of where the pharmaceutical company is aiming to take an important drug, which is approaching the end of its patent life. If BiotechCo can come up with a new improved delivery system, then you will assist Pharma Co in creating a significant market lead for their drug, and by so doing probably increase the chances of selling your portfolio of technologies to Pharma Co. You have set your best research brains on to the problem, and they have come up with a very clever device which uses technology that has been known outside the pharmaceutical sector for a non-medical purpose. Their developments have been reported to Pharma Co on a confidential basis and Pharma Co has been given a prototype. Pharma Co has done some tests on the device.

GlaxoSmithKline announces Q4 2010 legal charge

Industry news, News / 18 January 2011 / GlaxoSmithKline (GSK)

GSK expects to record a legal charge for the fourth quarter of 2010 of £2.2 billion ($3.4 billion)…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +